Resumen
Como ya se ha dicho en anteriores capítulos de este libro, en los últimos años se ha incrementado de manera exponencial el n úmero de evaluaciones económicas efectuadas y publicadas, debido en gran parte a la existencia de muchos países que emplean el criterio de la eficiencia en la toma de decisiones en política sanitaria. Dado que cada vez hay más evaluaciones económicas disponibles, cuando un profesional sanitario u otro decisor necesitan conocer datos de costeefectividad en su medio de influencia, antes de decidirse a efectuar una evaluación económica nueva, es lógico y coherente mirar a su alrededor y ver si existe algún análisis económico que le pueda servir para obtener los datos que necesita. Si los encuentra, deberá intentar generalizar y transferir estos datos al entorno donde esté y donde tiene que tomar la decisión, ya que de esta manera dispondrá de los datos de eficiencia mucho antes y con un coste mucho menor.
Hacer o no hacer algo, sólo depende de nuestra voluntad y perseverancia.
Albert Einstein
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
References
Birch S, Gafni A. Economics and the evaluation of healthcare programmes: generalisability of methods and implications for generalisability of results. Health Policy 2003; 64: 207–219.
Sculpher MJ, Drummond MF. Analysis sans Frontières: Can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 2006; 24: 1087–1099.
Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005; 8: 10–23.
McDonough CM, Tosteson ANA. Measuring preferences for cost-utility analysis. How choice of method may influence decision-making. Pharmacoeconomics 2007; 25: 93–106.
Dale PL, Hutton J, Elgazzar H. Utility of health state in chronic kidney disease: a structured review of the literature. Curr Med Res Opin 2008; 24: 193–206.
Welte R, Feenstra F, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22: 857–876.
Mason JM, Mason AR. The generalisability of pharmacoeconomic studies. Issues and challenges ahead. Pharmacoeconomics 2006; 24: 937–945.
Ortega Eslava A. Posibilidad de generalizar los resultados de una evaluación económica. Farm Hosp 2003; 27: 205–209.
Manca A, Willan AR. Lost in translation: accounting for between country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics 2006; 24: 1101–1109.
Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481–493.
Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based costeffectiveness analysis: the use of multilevel models. Health Econ 2005; 14: 471–485.
Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health 2009; 12: 409–418.
Goeree R, Burke N, O’Reilly D, Manca D, Blackhouse G, Tarride J-E. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007; 23: 671–682.
Urdahl H, Manca A, Sculpher M. Assessing generalisability in model-based economic evaluation studies. A structured review in osteoporosis. Pharmacoeconomics 2006; 24: 1181–1197.
Essers BA, Seferina SC, Tjan-Heijnen VCG, Severens Jl, Novak A, Pompen M, et al. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatments of HER-2 positive early breast cancer in the Netherlands. Value Health 2010; 13: 375–380.
Sculpher MJ, Pang FS, Manca A, Drummond MF. Generalisability in economic evaluation studies in health care: a review and case-studies. Health Technol Assess 2004; 8: 1–206.
Drummond M, Pang F. Transferability of economic evaluation results. In: Drummond M, McGuire A. editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001; 256–276.
Boulenger S, Nixon J, Drummond M, Ulmann D, Rice S, de Pouvourville G. Can economic evaluations be made more transferable? Eur J Health Econ 2005; 6: 334–346.
Turner S, Chase DL, Milne R, Cook A, Hicks NJ, Rosten C, et al. The health technology assessment adaptation toolkit: description and use. Int J Technol Assess Health Care 2009; 25 (Suppl 2): 37–41.
Goeree R, He J, O’Reilly D, Tarride JE, Xie F, Lim M, et al. Transferability of health technology assessment and economic evaluations: a systematic review of approaches for assessment and application. ClinicoEconomics Outcomes Research 2011; 3: 89–104.
Nixon J, Rice S, Drummond M, Boulenger S, Ulmann P, de Pourvourville G. Guidelines for completing the EURONHEED transferability information check-lists. Eur J Health Econ 2009; 10: 157–165.
Antoñanzas F, Rodríguez-Ibeas R, Juárez C, Hutter F, Lorente R, Pinillos M. Transferability indices for health economics evaluations: methods and applications. Health Econ 2009; 18: 629–643.
Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies. Int J Techn Assess Health Care 2005; 21: 165–171.
Chuen Li S. How to improve pharmacoeconomic data generalisability between different countries. Expert Opin Pharmacother 2007; 8: 1409–1413.
Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, et al. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health 2010; 13: 1028–1037.
Turk F. Data generalizability, data transferability, and the political economy of pharmacoeconomic guidelines. Value Health 2010; 13: 863–864.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2012 Springer Healthcare Iberica, S.L.
About this chapter
Cite this chapter
Soto Álvarez, J. (2012). TRANSFERENCIA Y ADAPTACIÓN DE LOS RESULTADOS DE EVALUACIONES ECONÓMICAS EFECTUADAS EN UN PAÍS Y ENTORNO SANITARIO A OTROS DIFERENTES. In: Evaluación económica de medicamentos y tecnologías sanitarias:. Springer Healthcare, Madrid. https://doi.org/10.1007/978-84-940346-6-4_17
Download citation
DOI: https://doi.org/10.1007/978-84-940346-6-4_17
Published:
Publisher Name: Springer Healthcare, Madrid
Print ISBN: 978-84-940346-1-9
Online ISBN: 978-84-940346-6-4
eBook Packages: MedicineMedicine (R0)